Arcturus Therapeutics is developing a portfolio of nucleic acid therapeutics for treatment of diseases with high unmet medical needs. Our hope and vision is to build transformative, life-changing medicines for patients and their families.
Our team has extensive experience in the discovery and development of RNA medicines, as well as design and utilization of lipid-mediated drug delivery systems. This combination of in-house expertise, innovative spirit, and passion for what we do, uniquely positions us to catalyze the next generation of nucleic medicines.
July 9, 2018
Arcturus Therapeutics Announces Results of Extraordinary General Meeting of Shareholders
June 18, 2018
Arcturus Therapeutics to Present at the JMP Securities Life Sciences Conference
May 31, 2018
Arcturus Announces Management Appointments; Company Founder Joseph E. Payne Reinstated as President and CEO